Corporate News

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes  the press release issued today by the UK Rapid Test Consortium (“UK-RTC”), of which Omega is a partner, welcoming a pre-print publication, funded by Public Health England (PHE), reviewing performance data on rapid antibody tests including the AbC-19^TM Rapid Test.

The study, performed by scientists at PHE, and the Universities of Bristol, Warwick and Cambridge, examined the performance of four lateral flow rapid antibody tests using the same cohort of sample, and shows that the AbC-19^TM is highly accurate when tested on samples from individuals previously positive for the virus by PCR and from samples collected pre-pandemic.

All devices tested had accuracy of above 92% with the AbC-19 ^TM Rapid Test showing the highest accuracy at 97.3%. The study remains subject to peer review.

The AbC-19^TM Rapid test confirms the presence of SARS-CoV-2 IgG neutralising antibodies to the spike protein of the COVID-19 virus in a small blood sample. These neutralizing antibodies may be produced as part of the body’s immune response following COVID-19 infection or post-vaccination. They not only bind to a virus, but they bind in a manner that blocks infection.

Professor Chris Molloy, Chair of the UK-RTC, said: “This research on the different use cases for lateral flow antibody tests is welcome. The AbC-19 ^TM test is an important weapon in the global fight against COVID-19. It allows us to see the neutralising IgG antibodies produced in response to infection, or after vaccination.”

The UK-RTC press release can be read in full here: https://www.abc19.com/

Contacts: